Piramal Pharma Limited has informed the Exchange regarding Appointment of Mr. Maneesh Sharma as Company Secretary & Compliance Officer of the company w.e.f. April 29, 2026.
PPLPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Piramal Pharma Limited held its Board meeting on April 28, 2026, approving FY2026 audited financial results. Standalone revenue stood at Rs 4,782 Crores (down from Rs 5,286 Crores YoY), with profit after tax of Rs 700 Crores (vs Rs 691 Crores). Consolidated revenue was Rs 8,869 Crores (vs Rs 9,151 Crores), but the company reported a consolidated loss after tax of Rs 326 Crores, primarily due to exceptional items including Rs 196 Crores in impairment and labour code impact. The Board re-appointed Ms. Nandini Piramal as Whole-Time Director and Chairperson for 3 years from April 2027, Mr. Peter DeYoung as Whole-Time Director for 3 years from October 2026, and two Independent Directors (Mr. Sridhar Gorthi and Mr. Peter Stevenson) for second terms of 5 years each. Mr. Maneesh Sharma was appointed as Company Secretary and Compliance Officer (KMP) effective April 29, 2026, replacing Ms. Pratibha Mishra who was interim. The registered office address will change effective April 30, 2026.
The standalone business remains profitable, but the consolidated loss reflects challenges including asset impairment and labour code adjustments. Leadership continuity with the Piramal family and experienced independent directors provides stability. The appointment of a permanent Company Secretary strengthens compliance governance.